A Clinical Study on Siddha Regimen ARPIAM for the management of Kudiveri Noi (Alcohol Use Disorder)-conducted at Ayothidoss Pandithar Hospital, National Institute of Siddha

Pilot Study on Multi drug Siddha Regimen ARPIAM for the Management of Kudiveri Noi (Alcohol Use Disorder):An open-Label-Single arm Clinical Trial Conducted at Ayothidoss Pandithar Hospital - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106747

Enrollment

Registered

2026-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F109- Alcohol use, unspecified

Interventions

Intervention1: Arakku Thailam Pidangunaari Kudineer Amukkara Chooranam : Arakku Thailam Dosage : 20 ml (External) Weekly twice Pidangunaari Kudineer Dosage : 30 ml Dosing schedule : 2 times ( Morning

Eligibility

Inclusion criteria

Inclusion criteria: Age: 18-60 years Gender: All genders Participants diagnosed with Alcohol Use Disorder (AUD) as per ICD-10 criteria Participants with an alcohol consumption history of less than one year 5.History of Alcoholic Abuse (Alcoholic dependency confirmed by AUDIT questionnaire). 6. Subjects who are willing to quit Alcohol., And give written informed consent and comply with study requirements 7.Willing to abstain from alcohol during the study period (48 days) and attend regular follow-ups 8.Willing to do Liver function tests, renal function, and hematological parameters

Exclusion criteria

Exclusion criteria: 1. Chronic disease like Cardiac disease, Hormonal imbalance and other psychiatric problem. 2. Substance abuse other than alcohol (Narcotics) 3. Pregnant and Lactating women 4. Withdrawal symptoms like Seizure, Delirium 5. Any other serious illness

Design outcomes

Primary

Measure	Time frame
Significant improvement in clinical signs and symptoms of alcohol dependence following administration of the Siddha formulations at the end of 48 daysTimepoint: Assessment for a participant - At the end of 48 days Over all study assessment - 17 and 18th Month of the Study (2 Months)	—

Secondary

Measure	Time frame
A marked decrease in the AUDIT (Alcohol Use Disorders Identification Test) score after treatment, indicating reduced alcohol consumption & dependence level. Enhanced overall physical, psychological, & social well-being of participants as reflected by improved Quality of Life scores. Noticeable decline in alcohol craving levels assessed through the Alcohol Craving Questionnaire Short Form Revised (ACQ-SF-R), confirming the efficacy of the intervention in craving control. Restoration of altered liver function parameters (serum bilirubin, AST, ALT, ALP, GGT) and lipid profile values toward normal limits after treatment. Maintenance of hematological, hepatic, & renal function markers within permissible limits throughout the study period, ensuring the safety of the Siddha formulations will be assessed at the end of 48 daysTimepoint: Assessment for a participant - At the end of 48 days Over all study assessment - 17 & 18th Month of the Study (2 Months)	—

Measure

Time frame

A marked decrease in the AUDIT (Alcohol Use Disorders Identification Test) score after treatment, indicating reduced alcohol consumption & dependence level. Enhanced overall physical, psychological, & social well-being of participants as reflected by improved Quality of Life scores. Noticeable decline in alcohol craving levels assessed through the Alcohol Craving Questionnaire Short Form Revised (ACQ-SF-R), confirming the efficacy of the intervention in craving control. Restoration of altered liver function parameters (serum bilirubin, AST, ALT, ALP, GGT) and lipid profile values toward normal limits after treatment. Maintenance of hematological, hepatic, & renal function markers within permissible limits throughout the study period, ensuring the safety of the Siddha formulations will be assessed at the end of 48 daysTimepoint: Assessment for a participant - At the end of 48 days Over all study assessment - 17 & 18th Month of the Study (2 Months)

—

Countries

India

Contacts

Public ContactProf Dr S Murugesan

National Institute of Siddha

sathishadithya.nis@gov.in9994990179

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026